机构:[1]Department of Otorhinolaryngology, Zhujiang Hospital of Southern Medical University, Guangzhou 510280, China南方医科大学珠江医院[2]Department of Otorhinolaryngology, The First People’s Hospital of Yunnan Province, The Affiliated Hospital of Kunming University of Science and Technology, Kunming 650032, China外科片耳鼻喉科云南省第一人民医院[3]Department of Genetic Diagnosis Center, The First People’s Hospital of Yunnan Province, Kunming 650032, China门急诊片医学遗传科云南省第一人民医院
Background: The cause of sudden sensorineural hearing loss (SSNHL) is still unknown. Literature has indicated that there is a statistically significant correlation between hyperhomocysteinemia and SSNHL, yet there is lack of study in the relationship concerning total frequency deafness subtype of SSNHL. This study investigated the relationship between plasma concentration of homocysteine (Hcy), serum concentration of folic acid and occurrence and treatment responding in total frequency deafness adult patients, and explored whether targeted early intervention was associated with improved clinical outcome in this subgroup. Methods: A total of 54 consecutive adult patients with diagnosis of sudden total frequency deafness in a single institution was enrolled into the study group. Two control groups were established. Control group 1 was derived from inpatients with normal listening comprehension. Control group 2 included 52 patients with sudden total frequency deafness treated in a parallel hospital. Blood concentration of folic acid and Hcy was investigated. Treatment included Ginkgo biloba extract, dexamethasone, hyperbaric oxygen, folic acid, vitamin B6, and optional vitamin B12. All data was statistically analyzed. Blood level of Hcy and folic acid was compared between study group and control group 1. Results: Although there was no clear evidence for the divergence trend of Hcy and folic acid levels individually, the results showed that the study group had higher blood level of Hcy and lower blood level of folic acid, than control group. In the study group, 24 patients (44.44%) demonstrated treatment effectiveness after the 2-week treatment course. Patients without vertigo had higher effective rate than patients with vertigo (P<0.05). Conclusions: Effective rate of study group was higher than control group 2 which had no folic acid and vitamin B6/B12 supplement. High blood Hcy and low blood folic acid were closely associated in patients with sudden total frequency deafness. The currently accepted concept of treatment for sudden total frequency deafness is not essentially satisfactory. Testing of plasma Hey and serum folic acid may provide referential value for its treatment and prognosis evaluation.
基金:
“KunHua AoXin
science and technology planning project” (2014–2017) and
“Genetic Diagnosis Center of laboratory open subject”
(2017ZDKFKT003) in the First People’s Hospital of
Yunnan Province.
第一作者机构:[1]Department of Otorhinolaryngology, Zhujiang Hospital of Southern Medical University, Guangzhou 510280, China[2]Department of Otorhinolaryngology, The First People’s Hospital of Yunnan Province, The Affiliated Hospital of Kunming University of Science and Technology, Kunming 650032, China
通讯作者:
通讯机构:[1]Department of Otorhinolaryngology, Zhujiang Hospital of Southern Medical University, Guangzhou 510280, China[*1]Department of Otorhinolaryngology, Zhujiang Hospital of Southern Medical University, Guangzhou 510280, China
推荐引用方式(GB/T 7714):
Huang Yang,Lv Tao,Xie Minqiang,et al.Blood homocysteine and folic acid levels may provide reference value for the treatment of sudden total frequency deafness[J].ANNALS OF PALLIATIVE MEDICINE.2019,8(5):604-610.doi:10.21037/apm.2019.10.08.
APA:
Huang, Yang,Lv, Tao,Xie, Minqiang,He, Jing,Pei, Jiahong...&Cao, Xianbao.(2019).Blood homocysteine and folic acid levels may provide reference value for the treatment of sudden total frequency deafness.ANNALS OF PALLIATIVE MEDICINE,8,(5)
MLA:
Huang, Yang,et al."Blood homocysteine and folic acid levels may provide reference value for the treatment of sudden total frequency deafness".ANNALS OF PALLIATIVE MEDICINE 8..5(2019):604-610